Physician profile
Neeta Soni
NPI 1639116734
$5,789.80
in general payments reported to CMS, 2019-2025
18 companies · $30.65 in 2025
The $30.65 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,256 · 2020: $900 · 2021: $1,133 · 2023: $1,470 · 2025: $30.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,388 · Food and Beverage: $82.30 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,387.50 |
| Food and Beverage | $82.30 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,594.80 | 2019-2023 | Imfinzi |
| Seagen INC. | $1,460.71 | 2019 | |
| Coherus Oncology, INC. | $1,100.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $915.53 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $233.00 | 2019 | |
| Abbvie INC. | $110.38 | 2019 | |
| Celgene Corporation | $83.52 | 2019 | |
| Genentech USA, INC. | $83.50 | 2019 | |
| Pfizer INC. | $41.76 | 2019-2025 | |
| Lilly USA, LLC | $24.38 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.28 | 2019 | |
| Astellas Pharma US INC | $20.96 | 2019 | |
| Janssen Biotech, INC. | $20.96 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.24 | 2019 | |
| Verastem, INC. | $17.92 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $15.84 | 2019 | |
| Merck Sharp & Dohme LLC | $12.10 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeta Soni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.